Endpoints News 生物医药· Reynald Castaneda·· 4 天前AI 评分60
CG Oncology 的膀胱癌治疗在 III 期试验中超出预期
CG Oncology's bladder cancer treatment beats expectations in Phase 3
AI 导读
CG Oncology 的免疫治疗在 III 期试验中对某些非肌肉浸润膀胱癌患者表现出色,可能显著扩大该产品的市场。
正文
CG Oncology said its oncolytic immunotherapy succeeded in a late-stage trial in certain patients with non-muscle invasive bladder cancer, potentially expanding the asset’s market significantly.
…
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news